From the *Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland
†Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina
‡Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
§Division of Cardiothoracic Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland.
Submitted for consideration January 2022; accepted for publication in revised form June 2022.
Disclosure: R.T. reports general disclosures to include consulting relationships with Medtronic, Abbott, Aria CV Inc., Acceleron, Itamar, Edwards LifeSciences, Eidos Therapeutics, Lexicon Pharmaceuticals, Gradient and United Therapeutics. He is on a steering committee for Medtronic, Acceleron, and Abbott as well as on a research advisory board for Abiomed. He also does hemodynamic core lab work for Actelion and Merck. The other authors have no conflicts of interest to report..
S.H. received the following sources of funding: P.I., NIH/NHLBI K23-HL146889-01; Co-investigator., NIH/NHLBI R01-HL114910-06.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal’s Web site (www.asaiojournal.com).
Correspondence: Steven Hsu, MD, FACC, Johns Hopkins University School of Medicine, 1800 Orleans St/ Zayed 7125-S, Baltimore, MD 21287. Email: [email protected]
